During the corresponding time, Brainsway Ltd recorded a revenue increase by 27.33 % year on year, While revenue at the Brainsway Ltd 's corporate clients
Brainsway Ltd's Comment on Sales, Marketing and Customers
The company provides its Deep TMS system to customers, requiring adequate coverage and reimbursement for authorized indications. Physicians represent a key market segment, as their willingness to use or recommend Deep TMS influences sales. The company depends on third parties, including suppliers for components, distributors for international marketing and promotion, and organizations conducting clinical trials. Additionally, the company holds minority stakes in Neurolief and Management Service Organizations (MSOs).
In a significant advancement in the field of mental health treatment, BrainsWay Ltd has received FDA clearance for its Deep Transcranial Magnetic Stimulation (Deep TMS) technology as an adjunct therapy for Major Depressive Disorder (MDD) in adolescents aged 15 to 21. This pivotal endorsement marks Deep TMS as the first and only transcranial magnetic stimulation device authorized for the treatment of patients ranging from 15 to 86 years old grappling with depression.The FDA clearance represents a major triumph for BrainsWay at a time when adolescent mental health issues are climbing to concerning levels. Statistics show that approximately 1 in 5 youth aged 13-18 experiences a severe mental disorder at some po...
BURLINGTON, Mass. and JERUSALEM, Jan. 10, 2024 BrainsWay Ltd. (NASDAQ and TASE: BWAY), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, has announced strategic advancements aimed at enhancing the clinical application and market appeal of its Deep Transcranial Magnetic Stimulation (Deep TMS) technology. The company has initiated a prospective, randomized, controlled, multicenter trial to evaluate an accelerated version of its Deep TMS treatment for Major Depressive Disorder (MDD). Concurrently, BrainsWay will begin clinical evaluation of the innovative Rotational Field Deep TMS 360 technology in two new feasibility trials. Accelerated Deep TMS for DepressionT...
In the ever-evolving landscape of mental health treatment, BrainsWay Ltd and Katies Way have emerged as groundbreaking leaders, making significant strides in providing lifesaving mental health treatment nationally, with a specific focus on servicemembers, veterans, and their families. As BrainsWay Ltd experiences a slight decline in revenue, its partnership with Katies Way Plus proves to be an instrumental force in revolutionizing the field of mental health. This article will delve into the significance of this partnership, the impact of Katies Way Plus s national reach, and the future prospects of BrainsWay Ltd in the mental health sector.The Power of Partnership:BrainsWay Ltd s recent partnership expansion...
BrainsWay Ltd., a renowned global leader in advanced noninvasive neurostimulation treatments for mental health disorders, has announced its increased collaboration with a growing mental health treatment provider in the Western region of the United States. This collaboration has resulted in successive orders, ultimately leading to seven installed Deep Transcranial Magnetic Stimulation (Deep TMS) systems for the provider. This development indicates a positive trend for BrainsWay in terms of network expansion and future growth opportunities. Deep TMS is a cutting-edge technology that offers noninvasive and advanced neurostimulation treatments for mental health disorders. Its innovative techniques ...
Brainsway Ltd’s Comment on Sales, Marketing and Customers
The company provides its Deep TMS system to customers, requiring adequate coverage and reimbursement for authorized indications. Physicians represent a key market segment, as their willingness to use or recommend Deep TMS influences sales. The company depends on third parties, including suppliers for components, distributors for international marketing and promotion, and organizations conducting clinical trials. Additionally, the company holds minority stakes in Neurolief and Management Service Organizations (MSOs).
Sources:
Brainsway Ltd’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Brainsway Ltd’s corporate clients.
For your research, we’ve provided 9 tables on Brainsway Ltd corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
